MEDIZINISCHE HOCHSCHULE BRANDENBURG CAMPUS GMBH

Their core work

Brandenburg Medical School is a German private medical university based in Neuruppin that combines clinical medicine education with applied health research. In H2020, they contributed to two distinct research tracks: the safety implications of low-dose medical radiation exposure (MEDIRAD), and the development of rapid point-of-care diagnostics for viral haemorrhagic fevers including Ebola (VHFMoDRAD). Their most defined research identity lies in bedside diagnostic technologies — lateral flow assays (LFA), recombinase polymerase amplification (RPA), and multiplex detection platforms — aimed at enabling rapid early detection in resource-limited or emergency settings. They also carry a capacity-building and twinning role, suggesting involvement in transferring diagnostic capabilities to partner institutions, likely in lower-income or outbreak-prone regions.

What they specialise in

How they've shifted over time

Their first H2020 project (MEDIRAD, 2017) sat within radiation medicine — a conventional clinical research domain with no specific technology keywords recorded, suggesting a supporting or clinical-validation role within that consortium. By 2019, their focus shifted markedly toward infectious disease diagnostics, particularly rapid-response tools for Ebola and other viral haemorrhagic fevers, with a clear emphasis on field-deployable and multiplex technologies. The trajectory is a move from established clinical medicine toward applied diagnostic innovation for global health emergencies — a significant and deliberate shift in research identity.

Brandenburg Medical School is positioning itself at the intersection of epidemic preparedness and point-of-care diagnostics — a field that has seen substantial EU and global investment momentum since the West African Ebola outbreak and COVID-19 pandemic.

How they like to work

Brandenburg Medical School has participated in both H2020 projects exclusively as a consortium member, never as coordinator — consistent with an institution building research capacity and reputation rather than leading large programmes. The 50 unique partners from just 2 projects indicates membership in large, internationally distributed consortia typical of health research RIAs. This profile suggests they function as a specialist clinical contributor: providing medical expertise, patient or sample access, or validation capabilities within broader multi-partner efforts.

Despite only two projects, Brandenburg Medical School has connected with 50 unique consortium partners across 17 countries — a sign of large, internationally structured consortia. Given the Ebola and VHF focus of their most keyword-rich project, their network likely includes African research institutions and public health bodies alongside European academic and industrial partners.

What sets them apart

As a medical school rather than a traditional research university, Brandenburg brings a clinical medicine grounding that is valuable for translational projects requiring medical validation, patient-facing perspectives, or healthcare system linkages. Their combination of radiation medicine and infectious disease diagnostics expertise within a single small institution is uncommon and makes them a versatile specialist partner. For consortium builders targeting both European clinical research and global health diagnostic challenges, they offer a credentialed academic anchor with demonstrated cross-domain reach.

Highlights from their portfolio

• VHFMoDRAD
  This project is their most technically specific engagement, developing multiplex rapid diagnostics for Ebola and other viral haemorrhagic fevers using LFA and RPA technologies — directly relevant to global epidemic preparedness and a growing EU health security priority.
• MEDIRAD
  Their earliest H2020 project and largest by consortium scale, addressing a clinically significant and policy-relevant question about radiation safety in medical imaging — a topic with direct public health and regulatory implications across Europe.